Bachem at Spring 2025 events

Bubendorf, Switzerland: –Specialist CDMO Bachem AG will be represented at three key peptide and oligo-related events, all occurring during March 2025 in Europe and North America.

The first of these will be the RNA Leaders Europe Congress 2025 in Basel, Switzerland, a networking conference opening on March 6 that aims to unite innovation leaders in genetic medicine with the right partners to drive forward RNA development.

The Congress program features scientific tracks covering in-depth development strategies, trends and technologies across the entire long and small RNA spectrum.

Representing Bachem in Basel will be Business Development Managers Daniel Bachmann and Mathias Beysard, the latter specializing in oligonucleotides.

OPT Congress Boston

Bachem’s second March 2025 event will be on March 11-12, in Boston, Massachusetts, for the oligonucleotide and peptide therapies OPT Congress, specializing in oligomer and mRNA-based therapeutics.

This conference provides a leading knowledge-sharing opportunity for scientists and clinicians involved in discovering and developing oligonucleotides as therapeutics. It aims to bring together leading discovery and development scientists, CMC and regulatory experts, and technology providers, to help optimize drug design and delivery, streamline manufacturing and regulatory issues and accelerate time to market.

Bachem’s representatives at the 2025 OPT Congress will be Senior. Bachem USA Business Development Managers Seema Zaidi and Joseph Fraone.

NextGen Biomed 2025

Bachem will also be present at the NextGen Biomed three-day conference in London opening on March 12. This biologics drug development forum unites some 30,000 biologics and immunotherapy R&D experts from six established industry communities; Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Biologics & TIDES, Immunotherapy & Immuno-Oncology, and Vaccines.

The meeting features a range of events and channels focused on building partnerships, aligning specialisms, bridging ‘unknowns’ and converting scientific discoveries into life-changing commercial cures.

Bachem’s representatives at the meeting will be Oligonucleotides Business Development Manager Mathias Beysard and Business Development Manager Vera D’Aloisio.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

For further information, see https://www.bachem.com

Resources

Click on RNA Leaders Congress 2025 for further event information and registration
Click on OPT Congress 2025 for further event information and registration
Click on NextGen Biomed 2025 for further event information and registration
Click on Bachems News to see latest News & Events.